Lymphoma  >>  Lonquex (lipegfilgrastim biosimilar)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lonquex (lipegfilgrastim biosimilar) / Teva
ACTRN12618000055202p: A study of the safety and effectiveness of Lipegfilgrastim, a growth factor, to prevent fever and infections ('febrile neutropenia') in patients undergoing chemotherapy for Non-Hodgkin Lymphoma (NHLL)

Not yet recruiting
4
30
 
Monash Health, TEVA pharmaceuticals
Non-Hodgkin Lymphoma
 
 
ACTRN12618000055202: A study of the safety and effectiveness of Lipegfilgrastim, a growth factor, to prevent fever and infections ('febrile neutropenia') in patients undergoing chemotherapy for Non-Hodgkin Lymphoma (NHLL)

Not yet recruiting
4
30
 
Monash Health, TEVA pharmaceuticals
Non-Hodgkin Lymphoma
 
 

Download Options